A multi-center double-blind placebo-controlled Phase 4 study in

Recruiting

99 years or below

All

Phase 4

4 participants needed

1 Location

Brief description of study

This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 sites in 12 countries.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: TBD
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 829514

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A multi-center double-blind placebo-controlled Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts

Brief description of study

Eligibility of study

Find a site

Interested in the study